Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Krupka

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Seminars in Hematology|June 27, 2015
Immunotherapy for Acute Myeloid LeukemiaFelix S Lichtenegger, Christina Krupka, Thomas Köhnke, et al.
Journal of Hematology & Oncology|October 10, 2015
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabThomas Köhnke, Christina Krupka, Johanna Tischer, et al.
Journal of Hematology & Oncology|July 27, 2017
Recent developments in immunotherapy of acute myeloid leukemiaFelix S Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Biomarker Research|June 10, 2022
Integrated multiomic approach for identification of novel immunotherapeutic targets in AMLThomas Köhnke, Xilong Liu, Sascha Haubner, et al.
Frontiers in Immunology|March 15, 2018
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting CellsFelix S Lichtenegger, Maurine Rothe, Frauke M Schnorfeil, et al.
Oncotarget|January 7, 2017
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cellsLaia Pascual Ponce, Nadja C Fenn, Nadine Moritz, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2015
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AMLFelix S Lichtenegger, Isabell Kondla, Michael Krempasky, et al.
Blood|October 3, 2018
Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemiaMonika Herrmann, Christina Krupka, Katrin Deiser, et al.
Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.
Plos One|March 21, 2015
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingBinje Vick, Maja Rothenberg, Nadine Sandhöfer, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Seminars in Hematology|June 27, 2015
Immunotherapy for Acute Myeloid LeukemiaFelix S Lichtenegger, Christina Krupka, Thomas Köhnke, et al.
Journal of Hematology & Oncology|October 10, 2015
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabThomas Köhnke, Christina Krupka, Johanna Tischer, et al.
Journal of Hematology & Oncology|July 27, 2017
Recent developments in immunotherapy of acute myeloid leukemiaFelix S Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Biomarker Research|June 10, 2022
Integrated multiomic approach for identification of novel immunotherapeutic targets in AMLThomas Köhnke, Xilong Liu, Sascha Haubner, et al.
Frontiers in Immunology|March 15, 2018
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting CellsFelix S Lichtenegger, Maurine Rothe, Frauke M Schnorfeil, et al.
Oncotarget|January 7, 2017
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cellsLaia Pascual Ponce, Nadja C Fenn, Nadine Moritz, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2015
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AMLFelix S Lichtenegger, Isabell Kondla, Michael Krempasky, et al.
Blood|October 3, 2018
Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemiaMonika Herrmann, Christina Krupka, Katrin Deiser, et al.
Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.
Plos One|March 21, 2015
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingBinje Vick, Maja Rothenberg, Nadine Sandhöfer, et al.
Pageof 2